- Home
- LWAY vs MREO Comparison
LWAY vs MREO Comparison
Compare LWAY & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAY
- MREO
- Stock Information
- Founded
- LWAY 1986
- MREO 2015
- Country
- LWAY United States
- MREO United Kingdom
- Employees
- LWAY N/A
- MREO 36
- Industry
- LWAY Packaged Foods
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- LWAY Consumer Staples
- MREO Health Care
- Exchange
- LWAY Nasdaq
- MREO Nasdaq
- Market Cap
- LWAY 464.0M
- MREO 281.6M
- IPO Year
- LWAY 1987
- MREO N/A
- Fundamental
- Price
- LWAY $31.01
- MREO $1.78
- Analyst Decision
- LWAY Buy
- MREO Strong Buy
- Analyst Count
- LWAY 2
- MREO 5
- Target Price
- LWAY $33.00
- MREO $7.40
- AVG Volume (30 Days)
- LWAY 75.0K
- MREO 1.2M
- Earning Date
- LWAY 08-12-2025
- MREO 08-12-2025
- Dividend Yield
- LWAY N/A
- MREO N/A
- EPS Growth
- LWAY N/A
- MREO N/A
- EPS
- LWAY 0.70
- MREO N/A
- Revenue
- LWAY $193,021,000.00
- MREO $500,000.00
- Revenue This Year
- LWAY $14.66
- MREO N/A
- Revenue Next Year
- LWAY $13.81
- MREO $55.50
- P/E Ratio
- LWAY $44.24
- MREO N/A
- Revenue Growth
- LWAY 9.19
- MREO N/A
- 52 Week Low
- LWAY $19.50
- MREO $1.47
- 52 Week High
- LWAY $32.20
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- LWAY 61.56
- MREO 51.99
- Support Level
- LWAY $28.55
- MREO $1.68
- Resistance Level
- LWAY $31.47
- MREO $1.83
- Average True Range (ATR)
- LWAY 1.17
- MREO 0.08
- MACD
- LWAY -0.13
- MREO 0.02
- Stochastic Oscillator
- LWAY 67.58
- MREO 78.26
About LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).